Identification and clinical validation of NUSAP1 as a novel prognostic biomarker in ovarian cancer

BMC Cancer

Table 5 Cox regression model analysis of overall survival in patients with serous ovarian cancer

Variables	Univariate analysis			Multivariate analysis
Variables	HR	95% CI of HR	P-value	HR	95% CI of HR	P-value
Serous ovarian cancer
NUSAP1 expression (low vs. high)	8.234	1.027–65.981	0.047*	6.339	0.644–62.387	0.113
Age (years) (< 60 vs. ≥ 60)	3.381	0.969–11.802	0.056	2.564	0.657–10.005	0.175
FIGO stage (I-II vs. III-IV)	39.941	0.189–8433.010	0.177	233,779.033	0.000–1.579E + 217	0.960
Tumor grade (1–2 vs. 3)	0.398	0.085–1.854	0.240	0.370	0.067–2.044	0.254
Lymph node metastasis (no vs. yes)	1.370	0.397–4.726	0.619	1.093	0.417–2.867	0.857
Residual tumor size (≤ 1 cm vs. > 1 cm)	5.800	1.119–30.054	0.036*	1.845	0.428 -7.948	0.411
HGSC
NUSAP1 expression (low vs. high)	5.851	0.706–48.468	0.101	1.648	0.161–16.852	0.674
Age (years) (< 60 vs. ≥ 60)	3.463	0.816–14.692	0.092	1.969	0.391–9.907	0.411
FIGO stage (I-II vs. III-IV)	36.733	0.057–23,576.497	0.266	200,211.029	0.000–1.573E + 287	0.971
Lymph node metastasis (no vs. yes)	0.357	0.044–2.913	0.336	0.296	0.026–3.353	0.325
Residual tumor size (≤ 1 cm vs. > 1 cm)	13.416	1.861–96.709	0.010*	12.161	1.329–111.235	0.027*

ISSN: 1471-2407